Guardian Competitors
| GRDN Stock | 30.20 0.48 1.56% |
Guardian Pharmacy vs Edgewise Therapeutics Correlation
Weak diversification
The correlation between Guardian Pharmacy Services and EWTX is 0.3 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Guardian Pharmacy Services and EWTX in the same portfolio, assuming nothing else is changed.
Moving against Guardian Stock
| 0.59 | HCWC | Healthy Choice Wellness | PairCorr |
| 0.54 | KR | Kroger Company | PairCorr |
| 0.5 | PFGC | Performance Food Earnings Call This Week | PairCorr |
| 0.46 | GO | Grocery Outlet Holding | PairCorr |
| 0.31 | IMKTA | Ingles Markets Earnings Call This Week | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Guardian Pharmacy's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Guardian Pharmacy Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Guardian Pharmacy and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Guardian and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Guardian Pharmacy does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Guardian Stock performing well and Guardian Pharmacy Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Guardian Pharmacy's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| TXG | 3.34 | 0.68 | 0.24 | 0.39 | 2.54 | 10.23 | 23.84 | |||
| PRCT | 2.75 | (0.32) | 0.00 | (0.12) | 0.00 | 7.06 | 17.63 | |||
| TWST | 3.09 | 0.45 | 0.13 | 0.66 | 3.10 | 7.37 | 17.30 | |||
| NUVB | 4.04 | 0.32 | 0.06 | 0.32 | 4.63 | 6.55 | 68.61 | |||
| NHC | 1.34 | 0.17 | 0.09 | 0.25 | 1.62 | 2.84 | 9.28 | |||
| QDEL | 3.24 | (0.07) | 0.00 | (0.09) | 0.00 | 8.12 | 24.99 | |||
| MD | 1.85 | 0.28 | 0.13 | 0.47 | 1.84 | 3.16 | 28.51 | |||
| MESO | 2.53 | 0.05 | 0.03 | 0.08 | 3.09 | 5.49 | 19.08 | |||
| JANX | 3.52 | (0.54) | 0.00 | (0.36) | 0.00 | 9.48 | 63.52 | |||
| EWTX | 4.24 | 1.11 | 0.24 | 1.24 | 4.04 | 14.33 | 38.85 |
Cross Equities Net Income Analysis
Compare Guardian Pharmacy and related stocks such as 10X Genomics, Procept Biorobotics Corp, and Twist Bioscience Corp Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TXG | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (112.5 M) | (31.3 M) | (542.7 M) | (58.2 M) | (166 M) | (255.1 M) | (182.6 M) | (164.4 M) | (172.6 M) |
| PRCT | (42 M) | (42 M) | (42 M) | (42 M) | (42 M) | (42 M) | (42 M) | (42 M) | (42 M) | (42 M) | (53 M) | (59.9 M) | (87.2 M) | (105.9 M) | (91.4 M) | (82.3 M) | (86.4 M) |
| TWST | (44.1 M) | (44.1 M) | (44.1 M) | (44.1 M) | (44.1 M) | (44.1 M) | (59.3 M) | (71.2 M) | (107.7 M) | (139.9 M) | (152.1 M) | (217.9 M) | (204.6 M) | (208.7 M) | (77.7 M) | (69.9 M) | (73.4 M) |
| NUVB | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (33.6 M) | (41.7 M) | (86.8 M) | (104.2 M) | (75.8 M) | (567.9 M) | (511.1 M) | (485.6 M) |
| NHC | 17.7 M | 65 M | 59.3 M | 64.6 M | 53.4 M | 53.1 M | 50.5 M | 56.2 M | 59 M | 68.2 M | 41.9 M | 138.6 M | 22.4 M | 66.8 M | 101.9 M | 117.2 M | 123.1 M |
| QDEL | (100 K) | 7.6 M | 5 M | 7.4 M | (7.1 M) | (6.1 M) | (13.8 M) | (8.2 M) | 74.2 M | 72.9 M | 810.3 M | 704.2 M | 548.7 M | (10.1 M) | (2.1 B) | (1.8 B) | (1.8 B) |
| MD | 5.4 M | 218 M | 240.9 M | 280.5 M | 317.3 M | 336.3 M | 324.9 M | 320.4 M | 268.6 M | (1.5 B) | (796.5 M) | 131 M | 66.3 M | (60.4 M) | (99.1 M) | (89.2 M) | (84.7 M) |
| MESO | (1.5 M) | (71.1 M) | (61.7 M) | (81 M) | (119.4 M) | (4.1 M) | (76.8 M) | (35.3 M) | (89.8 M) | (77.9 M) | (98.8 M) | (91.3 M) | (81.9 M) | (88 M) | (102.1 M) | (91.9 M) | (87.3 M) |
| JANX | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (6.8 M) | (32.6 M) | (54.2 M) | (58.3 M) | (69 M) | (62.1 M) | (59 M) |
| EWTX | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (17.1 M) | (42.1 M) | (15.4 M) | (100.2 M) | (133.8 M) | (120.4 M) | (114.4 M) |
Guardian Pharmacy and related stocks such as 10X Genomics, Procept Biorobotics Corp, and Twist Bioscience Corp Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Guardian Pharmacy financial statement analysis. It represents the amount of money remaining after all of Guardian Pharmacy Services operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Guardian Pharmacy Competitive Analysis
The better you understand Guardian Pharmacy competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Guardian Pharmacy's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Guardian Pharmacy's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Guardian Pharmacy Competition Performance Charts
Five steps to successful analysis of Guardian Pharmacy Competition
Guardian Pharmacy's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Guardian Pharmacy in relation to its competition. Guardian Pharmacy's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Guardian Pharmacy in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Guardian Pharmacy's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Guardian Pharmacy, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Guardian Pharmacy position
In addition to having Guardian Pharmacy in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investment Grade ETFs Thematic Idea Now
Investment Grade ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Investment Grade ETFs theme has 335 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investment Grade ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Guardian Pharmacy Correlation with its peers. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Will Consumer Staples Distribution & Retail sector continue expanding? Could Guardian diversify its offerings? Factors like these will boost the valuation of Guardian Pharmacy. Market participants price Guardian higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Guardian Pharmacy data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.68 | Revenue Per Share | Quarterly Revenue Growth 0.2 | Return On Assets | Return On Equity |
Understanding Guardian Pharmacy requires distinguishing between market price and book value, where the latter reflects Guardian's accounting equity. The concept of intrinsic value—what Guardian Pharmacy's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Guardian Pharmacy's price substantially above or below its fundamental value.
Please note, there is a significant difference between Guardian Pharmacy's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardian Pharmacy is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Guardian Pharmacy's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.